3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
13
Venous Thromboembolism
11
Venous Thrombosis
4
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Thrombosis
2
Pulmonary Embolism
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Pancreatic Neoplasms
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Interventions
Gemcitabine
60
Cisplatin
38
Oxaliplatin
30
Capecitabine
28
Fluorouracil
21
Leucovorin
19
pembrolizumab
11
Irinotecan
11
durvalumab
9
130-nm albumin-bound paclitaxel
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Platinum
6
Magnetic Resonance Spectroscopy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Taxes
5
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Carboplatin
5
Docetaxel
4
Biopsy
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Paclitaxel
3
Lapatinib
3
Interleukin-12 Subunit p35
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gallbladder Neoplasms
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled